Dylan Dupuis
Stock Analyst at Roth MKM
(2.78)
# 1,976
Out of 5,058 analysts
8
Total ratings
50%
Success rate
43.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dylan Dupuis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $28 | $2.43 | +1,052.26% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $3.94 | +179.19% | 2 | Sep 21, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $26.11 | -11.91% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $34.27 | -6.62% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $28
Current: $2.43
Upside: +1,052.26%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $3.94
Upside: +179.19%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $26.11
Upside: -11.91%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $34.27
Upside: -6.62%